Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Juthamas Sukbuntherng"'
Supplementary Figure S3. Response of cell signaling pathways to treatment with ibrutinib in multiple cell lines. Cells were treated for 1 hour with ibrutinib. 50,000 cells were loaded in each lane.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9ec84c461ecc62b2d44b50b3dac791
https://doi.org/10.1158/1535-7163.22508073.v1
https://doi.org/10.1158/1535-7163.22508073.v1
Supplementary Figure S2. Response of BT-474 (A) and SK-BR-3 (B) cells to treatment with different ErbB kinase inhibitors. The cells were treated with inhibitors continuously for 72 hours, and alamarBlue® assay was used to quantify cell growth.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::032b59d63d16ad874db1b4b2674bcdb0
https://doi.org/10.1158/1535-7163.22508076.v1
https://doi.org/10.1158/1535-7163.22508076.v1
Supplementary Tables 1 and 2; Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::accc43c0e25045a194223343dc03f1fd
https://doi.org/10.1158/1535-7163.22508064.v1
https://doi.org/10.1158/1535-7163.22508064.v1
Supplementary Figure S5. Ibrutinib irreversibly inhibited SK-BR-3 cells, and bound covalently to EGFR and HER4 in rapid dilution assays. (A) SK-BR-3 cells were treated with ibrutinib at 0.1 and 0.5 µM for varied times before washing twice with fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eb4ceab206717ec04678c4a164b75dd
https://doi.org/10.1158/1535-7163.22508067.v1
https://doi.org/10.1158/1535-7163.22508067.v1
Supplementary Figure S4. Ibrutinib inhibited the growth of BT-474 xenograft tumors and related signaling pathways in the tumor samples. (A) Inhibition of BT-474 xenograft growth in NOD-SCID mice by ibrutinib administered at once -daily doses of 3 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b54e5ed297905f65db178c4c5e9f917
https://doi.org/10.1158/1535-7163.22508070.v1
https://doi.org/10.1158/1535-7163.22508070.v1
Supplementary Figure S1. Response of MDA-MB-361 cells to multiple inhibitors. MD-MB-361 cells were plated in 96-well plates overnight before treatment with inhibitors for 72 hours. CellTiter-Glo® was used for quantifying cell growth. The assay was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5076069814bfcbd7bf81bc5d9e53c85d
https://doi.org/10.1158/1535-7163.22508079
https://doi.org/10.1158/1535-7163.22508079
Autor:
Monika Długosz-Danecka, Carlos Panizo, Tomasz Wróbel, Raul Cordoba, Wojciech Jurczak, Juthamas Sukbuntherng, James Jiao, Anna Mitselos, Peter Hellemans, Jan de Jong, Daniele Ouellet
Publikováno v:
Pharmacology Research & Perspectives
Ibrutinib may inhibit intestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary to potential induction, ibrutinib may reduce the exposure and effectiveness of oral contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the ph
Autor:
Carol Marimpietri, Mark Crowther, Taisei Kinoshita, Juthamas Sukbuntherng, Ahmad Mokatrin, Terrance D. Barrett, Betty Chang, Joi Ninomoto, Danelle F. James
Publikováno v:
Hematology (Amsterdam, Netherlands). 25(1)
Background: Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase (BTK), is approved in the US and EU for the treatment of various B-cell malignancies. In clinical studies, ...
Autor:
Juthamas Sukbuntherng, Sofie Mesens, Jan de Jong, Daniele Ouellet, Yuhan Huang, Peter Hellemans, James Jiao
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:1227-1237
Ibrutinib is an orally administered, irreversible Bruton’s tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarizati
Autor:
John C. Byrd, Paul M. Barr, Richard R. Furman, Jennifer R. Brown, Jan A. Burger, Jacqueline C. Barrientos, Tadeusz Robak, Juthamas Sukbuntherng, Susan O'Brien, George Cole, Marco Montillo, Steven Coutre, Claire Dearden, Samuel Suzuki, Danelle F. James, Stephen P. Mulligan, Peter Hillmen, John M. Pagel, Nishitha Reddy, Ulrich Jaeger, Carol Moreno, Florence Cymbalista
Publikováno v:
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It